PRS-220 is under clinical development by Pieris Pharmaceuticals and currently in Phase I for Idiopathic Pulmonary Fibrosis. According to GlobalData, Phase I drugs for Idiopathic Pulmonary Fibrosis have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PRS-220’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

PRS-220 overview

PRS-220 is under development for the treatment of idiopathic pulmonary fibrosis and for post-acute sequelae of SARS-CoV-2 infection (PASC) pulmonary fibrosis (PASC-PF). It is administered through inhalation route. The drug candidate is developed based on anticalin technology. It acts by targeting connective tissue growth factor (CTGF). 

Pieris Pharmaceuticals overview

Pieris Pharmaceuticals (Pieris) is a clinical-stage biotechnology company that carries out the discovery and development of anticalin-based drugs. The company’s pipeline product includes inhaled IL-4Ra antagonist Anticalin protein. It offers drug candidates such as PRS-060/AZD1402, PRS-220, PRS-440, PRS-342 and PRS-352, among others. Pieris also carries out AstraZenca programs and Genetech programs against respiratory diseases. The company offers therapeutics for the treatment of respiratory diseases, oncology and other diseases. It leverages Anticalin technology platform to develop and advance its pipeline candidates. Pieris collaborates with AstraZeneca Plc, Boston Pharmaceuticals, Servier SAS, Genentech and Seattle Genetics Inc to develop drug candidates. It operates in the US, Australia and Germany. Pieris is headquartered in Boston, Massachusetts, the US.

For a complete picture of PRS-220’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.